NIH-funded research R15 grant

Targeting a specific protein to improve treatment for oral cancer

Official title: Cadherins, contact normalization, and targeting podoplanin to treat oral cancer

Funded at Rowan University School/osteopathic Med · NIH-10437217 · Data updated 2026-11-12

This study is looking at how healthy cells can help slow down the growth of oral cancer cells by focusing on a protein called podoplanin, which is often found in higher amounts in oral cancer, and it aims to find new treatments that could help people with oral cancer feel better.

More Oral Cancer research and trials

Quick facts

Grant typeR15 grant
Study typeNIH-funded research
Funding institutionRowan University School/osteopathic Med
NIH-funded
Lab location1 site (Stratford, United States)
Project startApril 15, 2022
Project endMarch 31, 2026
Funding year2022
Award (this year)$482,998
NIH project number1R15CA271044-01
Project IDNIH-10437217 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with oral squamous cell carcinoma or precancerous oral lesions expressing high levels of podoplanin.

Less likely to help

Patients with non-cancerous oral conditions or those without elevated podoplanin levels may not benefit from this research.

What this research studies

This research investigates how nontransformed cells can influence the growth of oral cancer cells through a process called contact normalization. It focuses on the role of a protein called podoplanin, which is often overexpressed in oral squamous cell carcinoma (OSCC) and is linked to cancer progression. By understanding the mechanisms behind this interaction, the research aims to develop targeted therapies that could improve treatment outcomes for patients with oral cancer. The approach includes studying cell interactions and the effects of specific antibodies on cancer cell behavior.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that specifically target oral cancer, potentially improving survival rates and quality of life for patients.

How similar studies have gone: Other research has shown promise in targeting similar proteins in cancer treatment, suggesting that this approach could be effective.

Where this research is happening

  • Rowan University School/osteopathic Med
    Stratford, United States
    Active

Researchers

  • Principal investigator: Goldberg, Gary S — Rowan University School/osteopathic Med
  • Study coordinator: Goldberg, Gary S

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.